Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of PIZV (TAK-426) in Healthy Adults
NCT03343626Phase 1Completed
- Sponsor
- Takeda
- Start
- Nov 2017
- Primary completion
- Dec 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 1, randomised, single-blind trial of purified inactivated Zika virus vaccine in Zika virus infection (8 arms), sponsored by Takeda. Primary endpoints: Percentage of Participants With Solicited Local Injection Site Reactions at Day 36, Percentage of Participants With Solicited Systemic Adverse Events at Day 36 and 3 more. Started Nov 2017; status: completed.
02
Drugs
purified inactivated Zika virus vaccine
03
Conditions
Zika virus infection
Beyond the preview
Go deeper on NCT03343626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03343626.